Neoplasms, Hematologic Completed Phase 2 Trials for Panobinostat (DB06603)

Also known as: Hematologic Neoplasm / Hematologic Neoplasms

IndicationStatusPhase
DBCOND0056760 (Neoplasms, Hematologic)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01802879Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the InvestigatorTreatment